REFERENCES
1. Obaid G, Celli JP, Broekgaarden M, et al. Engineering photodynamics for treatment, priming and imaging. Nat Rev Bioeng 2024;2:752-69.
2. Dolmans DEJGJ, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer 2003;3:380-7.
3. Celli JP, Spring BQ, Rizvi I, et al. Imaging and photodynamic therapy: mechanisms, monitoring, and optimization. Chem Rev 2010;110:2795-838.
5. Ethirajan M, Chen Y, Joshi P, Pandey RK. The role of porphyrin chemistry in tumor imaging and photodynamic therapy. Chem Soc Rev 2011;40:340-62.
6. Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic therapy. J Natl Cancer Inst 1998;90:889-905.
7. Abrahamse H, Hamblin MR. New photosensitizers for photodynamic therapy. Biochem J 2016;473:347-64.
9. ClinicalTrials.gov. Treatment of primary breast cancer using PDT. Available from: https://clinicaltrials.gov/study/NCT02872064. [Last accessed on 13 Sep 2024].
10. ClinicalTrials.gov. An open label, phase II trial of continuous low-irradiance photodynamic therapy (CLIPT) using Verteporfin (Visudyne®) for the treatment of cutaneous metastases of breast cancer. Available from: https://clinicaltrials.gov/study/NCT02939274. [Last accessed on 13 Sep 2024].
11. ClinicalTrials.gov. Ultrasound-guided verteporfin photodynamic therapy for the treatment of unresectable solid pancreatic tumors or advanced pancreatic cancer, VERTPAC-02 study. Available from: https://clinicaltrials.gov/study/NCT03033225. [Last accessed on 13 Sep 2024].
12. ClinicalTrials.gov. Photodynamic therapy in treating patients with stage III or stage IV melanoma. Available from: https://clinicaltrials.gov/study/NCT00007969. [Last accessed on 13 Sep 2024].
13. ClinicalTrials.gov. Interstitial photodynamic therapy following palliative radiotherapy in treating patients with inoperable malignant central airway obstruction. Available from: https://clinicaltrials.gov/study/NCT06306638. [Last accessed on 13 Sep 2024].
14. ClinicalTrials.gov. Verteporfin for the treatment of recurrent high-grade EGFR-mutated glioblastoma. Available from: https://clinicaltrials.gov/study/NCT04590664. [Last accessed on 13 Sep 2024].
15. European Medicines Agency. Foscan. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/foscan. [Last accessed on 13 Sep 2024].
16. ClinicalTrials.gov. Single-arm study of photodynamic laser therapy using foscan for non-curatively-resectable bile duct carcinoma. Available from: https://clinicaltrials.gov/study/NCT01016002. [Last accessed on 13 Sep 2024].
17. ClinicalTrials.gov. Safety and tumoricidal effect of low dose foscan PDT in Patients with inoperable bile duct cancers (PDT). Available from: https://clinicaltrials.gov/study/NCT03003065. [Last accessed on 13 Sep 2024].
18. ClinicalTrials.gov. Photodynamic therapy during surgery in treating patients with non-small cell lung cancer that can be removed by surgery. Available from: https://clinicaltrials.gov/study/NCT01854684. [Last accessed on 13 Sep 2024].
19. Wang S, Bromley E, Xu L, Chen JC, Keltner L. Talaporfin sodium. Expert Opin Pharmacother 2010;11:133-40.
20. ClinicalTrials.gov. A phase 3 study of talaporfin sodium and interstitial light emitting diodes treating hepatocellular carcinoma (HCC). Available from: https://clinicaltrials.gov/study/NCT00355355. [Last accessed on 13 Sep 2024].
21. ClinicalTrials.gov. Tumor ablation with talaporfin sodium and interstitial light emitting diodes treating hepatocellular carcinoma (HCC). Available from: https://clinicaltrials.gov/study/NCT00122876. [Last accessed on 13 Sep 2024].
22. ClinicalTrials.gov. Photodynamic therapy with talaporfin sodium (LS11) in treating patients with refractory colorectal liver metastases. Available from: https://clinicaltrials.gov/study/NCT00068068. [Last accessed on 13 Sep 2024].
23. European Medicines Agency. EU/3/22/2602 - orphan designation for the treatment of biliary tract cancer. 2022. Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1470. [Last accessed on 13 Sep 2024].
24. Santos LL, Oliveira J, Monteiro E, Santos J, Sarmento C. Treatment of head and neck cancer with photodynamic therapy with redaporfin: a clinical case report. Case Rep Oncol 2018;11:769-76.
25. Dos Santos AF, Terra LF, Wailemann RA, et al. Methylene blue photodynamic therapy induces selective and massive cell death in human breast cancer cells. BMC Cancer 2017;17:194.
26. Tardivo JP, Del Giglio A, de Oliveira CS, et al. Methylene blue in photodynamic therapy: From basic mechanisms to clinical applications. Photodiagnosis Photodyn Ther 2005;2:175-91.
27. Fathy G, Asaad MK, Rasheed HM. Daylight photodynamic therapy with methylene blue in plane warts: a randomized double-blind placebo-controlled study. Photodermatol Photoimmunol Photomed 2017;33:185-92.
28. ClinicalTrials.gov. ICG-PDT, periimplantitis, diabetes mellitus. Available from: https://clinicaltrials.gov/study/NCT04833569. [Last accessed on 13 Sep 2024].
29. ClinicalTrials.gov. Single session of antimicrobial photodynamic therapy using indocyanine green. Available from: https://clinicaltrials.gov/study/NCT02043340. [Last accessed on 13 Sep 2024].
30. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist 2003;8:411-24.
31. Kim Y, Chen J. Molecular structure of human P-glycoprotein in the ATP-bound, outward-facing conformation. Science 2018;359:915-9.
32. Manolaridis I, Jackson SM, Taylor NMI, Kowal J, Stahlberg H, Locher KP. Cryo-EM structures of a human ABCG2 mutant trapped in ATP-bound and substrate-bound states. Nature 2018;563:426-30.
33. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003;55:3-29.
34. Gottesman MM, Lavi O, Hall MD, Gillet JP. Toward a better understanding of the complexity of cancer drug resistance. Annu Rev Pharmacol Toxicol 2016;56:85-102.
35. Tamaki A, Ierano C, Szakacs G, Robey RW, Bates SE. The controversial role of ABC transporters in clinical oncology. Essays Biochem 2011;50:209-32.
36. Baglo Y, Liang BJ, Robey RW, Ambudkar SV, Gottesman MM, Huang HC. Porphyrin-lipid assemblies and nanovesicles overcome ABC transporter-mediated photodynamic therapy resistance in cancer cells. Cancer Lett 2019;457:110-8.
37. Li W, Zhang WJ, Ohnishi K, Yamada I, Ohno R, Hashimoto K. 5-Aminolaevulinic acid-mediated photodynamic therapy in multidrug resistant leukemia cells. J Photochem Photobiol B 2001;60:79-86.
38. Robey RW, Steadman K, Polgar O, et al. Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res 2004;64:1242-6.
39. Jonker JW, Buitelaar M, Wagenaar E, et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A 2002;99:15649-54.
40. Merlin JL, Gautier H, Barberi-Heyob M, Teiten MH, Guillemin F. The multidrug resistance modulator SDZ-PSC 833 potentiates the photodynamic activity of chlorin e6 independently of P-glycoprotein in multidrug resistant human breast adenocarcinoma cells. Int J Oncol 2003;22:733-9.
41. Robey RW, Steadman K, Polgar O, Bates SE. ABCG2-mediated transport of photosensitizers: potential impact on photodynamic therapy. Cancer Biol Ther 2005;4:187-94.
42. Huang HC, Mallidi S, Liu J, et al. Photodynamic therapy synergizes with irinotecan to overcome compensatory mechanisms and improve treatment outcomes in pancreatic cancer. Cancer Res 2016;76:1066-77.
43. Aniogo EC, Plackal Adimuriyil George B, Abrahamse H. The role of photodynamic therapy on multidrug resistant breast cancer. Cancer Cell Int 2019;19:91.
44. Bartholomae S, Gruhn B, Debatin KM, et al. Co-expression of multiple ABC-transporters is strongly associated with treatment response in childhood acute myeloid leukemia. Pediatr Blood Cancer 2016;63:242-7.
45. Ween MP, Armstrong MA, Oehler MK, Ricciardelli C. The role of ABC transporters in ovarian cancer progression and chemoresistance. Crit Rev Oncol Hematol 2015;96:220-56.
46. Hlavata I, Mohelnikova-Duchonova B, Vaclavikova R, et al. The role of ABC transporters in progression and clinical outcome of colorectal cancer. Mutagenesis 2012;27:187-96.
47. Casas A, Di Venosa G, Hasan T, Al Batlle. Mechanisms of resistance to photodynamic therapy. Curr Med Chem 2011;18:2486-515.
48. Kukcinaviciute E, Sasnauskiene A, Dabkeviciene D, Kirveliene V, Jonusiene V. Effect of mTHPC-mediated photodynamic therapy on 5-fluorouracil resistant human colorectal cancer cells. Photochem Photobiol Sci 2017;16:1063-70.
49. Kim JH, Park JM, Roh YJ, Kim IW, Hasan T, Choi MG. Enhanced efficacy of photodynamic therapy by inhibiting ABCG2 in colon cancers. BMC Cancer 2015;15:504.
50. Liu FS. Mechanisms of chemotherapeutic drug resistance in cancer therapy--a quick review. Taiwan J Obstet Gynecol 2009;48:239-44.
51. Yuan Y, Chen K, Chen X, et al. Fumitremorgin C attenuates osteoclast formation and function via suppressing RANKL-induced signaling pathways. Front Pharmacol 2020;11:238.
52. Jackson SM, Manolaridis I, Kowal J, et al. Structural basis of small-molecule inhibition of human multidrug transporter ABCG2. Nat Struct Mol Biol 2018;25:333-40.
53. Nagaya T, Nakamura YA, Choyke PL, Kobayashi H. Fluorescence-guided surgery. Front Oncol 2017;7:314.
54. Liu W, Baer MR, Bowman MJ, et al. The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2. Clin Cancer Res 2007;13:2463-70.
55. Teiten MH, Bezdetnaya L, Merlin JL, et al. Effect of meta-tetra(hydroxyphenyl)chlorin (mTHPC)-mediated photodynamic therapy on sensitive and multidrug-resistant human breast cancer cells. J Photochem Photobiol B 2001;62:146-52.
56. Tsai T, Hong RL, Tsai JC, Lou PJ, Ling IF, Chen CT. Effect of 5-aminolevulinic acid-mediated photodynamic therapy on MCF-7 and MCF-7/ADR cells. Lasers Surg Med 2004;34:62-72.
57. Sajid A, Rahman H, Ambudkar SV. Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters. Nat Rev Cancer 2023;23:762-79.
58. Montanari F, Ecker GF. Prediction of drug-ABC-transporter interaction - recent advances and future challenges. Adv Drug Deliv Rev 2015;86:17-26.
59. Liang BJ, Lusvarghi S, Ambudkar SV, Huang HC. Mechanistic insights into photodynamic regulation of adenosine 5’-triphosphate-binding cassette drug transporters. ACS Pharmacol Transl Sci 2021;4:1578-87.
60. Palasuberniam P, Yang X, Kraus D, Jones P, Myers KA, Chen B. ABCG2 transporter inhibitor restores the sensitivity of triple negative breast cancer cells to aminolevulinic acid-mediated photodynamic therapy. Sci Rep 2015;5:13298.
61. Mansi M, Howley R, Chandratre S, Chen B. Inhibition of ABCG2 transporter by lapatinib enhances 5-aminolevulinic acid-mediated protoporphyrin IX fluorescence and photodynamic therapy response in human glioma cell lines. Biochem Pharmacol 2022;200:115031.
62. Lee HJ, Heo DS, Cho JY, et al. A phase i study of oral paclitaxel with a novel p-glycoprotein inhibitor, HM30181A, in patients with advanced solid cancer. Cancer Res Treat 2014;46:234-42.
63. Choi YH, Yu AM. ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr Pharm Des 2014;20:793-807.
64. Wu CP, Calcagno AM, Ambudkar SV. Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol 2008;1:93-105.
65. Shukla S, Chen ZS, Ambudkar SV. Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance. Drug Resist Updat 2012;15:70-80.
66. Wu CP, Hsiao SH, Huang YH, et al. Sitravatinib Sensitizes ABCB1- and ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs. Cancers 2020;12:195.
67. Rahman I, Liang B, Sajid A, Ambudkar SV, Huang HC. Photodynamic priming modulates cellular ATP levels to overcome P-glycoprotein-mediated drug efflux in chemoresistant triple-negative breast cancer. Photochem Photobiol 2024;Online ahead of print.
68. ClinicalTrials.gov. Photodynamic therapy in treating patients with cancer of the bile duct, gallbladder, or pancreas. Available from: https://clinicaltrials.gov/study/NCT00003923. [Last accessed on 13 Sep 2024].
69. Heinzelmann-Schwarz V, Fedier A, Hornung R, Walt H, Haller U, Fink D. Role of p53 and ATM in photodynamic therapy-induced apoptosis. Lasers Surg Med 2003;33:182-9.
70. Luna MC, Ferrario A, Wong S, Fisher AM, Gomer CJ. Photodynamic therapy-mediated oxidative stress as a molecular switch for the temporal expression of genes ligated to the human heat shock promoter. CancerRes 2000;60:1637-44.
